Drug Interaction and Pharmacist
Author:
Open Access
- 1 July 2010
- journal article
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 2 (3) , 326-331
Abstract
The topic of drug-drug interactions has received a great deal of recent attention from the regulatory, scientific, and health care communities worldwide. Nonsteroidal anti-inflammatory drugs, antibiotics and, in particular, rifampin are common precipitant drugs prescribed in primary care practice. Drugs with a narrow therapeutic range or low therapeutic index are more likely to be the objects for serious drug interactions. Object drugs in common use include warfarin, fluoroquinolones, antiepileptic drugs, oral contraceptives, cisapride, and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. The pharmacist, along with the prescriber has a duty to ensure that patients are aware of the risk of side effects and a suitable course of action should they occur. With their detailed knowledge of medicine, pharmacists have the ability to relate unexpected symptoms experienced by patients to possible adverse effects of their drug therapy.Keywords
This publication has 13 references indexed in Scilit:
- Multiple drug interactions - induced serotonin syndrome: a case reportJournal of Clinical Pharmacy and Therapeutics, 2009
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side EffectsNew England Journal of Medicine, 2003
- Inheritance and Drug ResponseNew England Journal of Medicine, 2003
- Pharmacogenetics in the Laboratory and the ClinicNew England Journal of Medicine, 2003
- Revisiting the Significance of Warfarin Protein-Binding Displacement InteractionsAnnals of Pharmacotherapy, 2002
- ACC/AHA/NHLBI clinical advisory on the use and safety of statins11When citing this document, the American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute would appreciate the following citation format: Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the Use and Safety of Statins. J Am Coll Cardiol 2002;40:568–73.22This document is available on the Web sites of the ACC (www.acc.org), the AHA (www.americanheart.org), and the NHLBI (www.nhlbi.nih.gov/guidelines/cholesterol).JACC, 2002
- The Role of Pharmacy Computer Systems in Preventing Medication ErrorsJournal of the American Pharmaceutical Association, 2002
- Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 2002
- Potential Role of Pharmacogenomics in Reducing Adverse Drug ReactionsJAMA, 2001
- Performance of Community Pharmacy Drug Interaction SoftwareJournal of the American Pharmaceutical Association, 2001